Omeros (OMER) Gains from Sales and Divestitures (2022 - 2023)
Omeros' (OMER) quarterly Gains from Sales and Divestitures came in at $67250.0 in Q4 2023, down 31.9% year-on-year from $98750.0 in Q4 2022, and down 31.9% quarter-over-quarter from $98750.0 in Q4 2022.
Omeros (OMER) Gains from Sales and Divestitures (2022 - 2023) Analysis & Trends
Omeros has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $67250.0 for Q4 2023.
- Gains from Sales and Divestitures for Q4 2023 came in at $67250.0, down 31.9% year-over-year; the trailing twelve-month figure through Dec 2023 was $67250.0 (down 31.9% YoY), and the FY2023 annual result was $67250.0, down 31.9% from the prior year.
- Gains from Sales and Divestitures came in at $67250.0 for Q4 2023 at Omeros, down from $98750.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $98750.0 in Q4 2022 to a low of $67250.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 67,250.00 |
| Dec 31, 2023 | 67,250.00 |
| Dec 31, 2022 | 98,750.00 |
| Dec 31, 2022 | 98,750.00 |